DrugPatentWatch Database Preview
Drugs in Development Information for PHA-793887
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug PHA-793887?
PHA-793887 is an investigational drug.
There have been 29 clinical trials for PHA-793887.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2014.
The most common disease conditions in clinical trials are Thymoma, HIV Infections, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), Nerviano Medical Sciences, and Pfizer.
There are two US patents protecting this investigational drug and fifty international patents.
Summary for PHA-793887
| US Patents | 2 |
| International Patents | 50 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2014-04-01) |
| Vendors | 61 |
Recent Clinical Trials for PHA-793887
| Title | Sponsor | Phase |
|---|---|---|
| The Benefit of Bermekimab in Patients With Systemic Sclerosis | Hellenic Institute for the Study of Sepsis | Phase 2 |
| ACTH vs Betamethasone in Hospitalized Patients With Acute Gout | University of Patras | N/A |
| The Effects of Nanocurcumin on Serum miRNA and Th17 Cells Development Factors in Ankylosing Spondylitis Patients | Stem Cell and Regenerative Medicine Institute, Tabriz, Iran | Phase 2 |
Clinical Trial Summary for PHA-793887
Top disease conditions for PHA-793887
Top clinical trial sponsors for PHA-793887
US Patents for PHA-793887
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PHA-793887 | Start Trial | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | Takara Bio Europe AB (Gothenburg, SE) | Start Trial |
| PHA-793887 | Start Trial | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | Pfizer Italia S.r.l. (Rome, IT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PHA-793887
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PHA-793887 | China | 105143445 | 2032-11-29 | Start Trial |
| PHA-793887 | European Patent Office | 2925859 | 2032-11-29 | Start Trial |
| PHA-793887 | European Patent Office | 3401391 | 2032-11-29 | Start Trial |
| PHA-793887 | Japan | 2016503304 | 2032-11-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
